BioLargo, Inc.
BLGO
$0.18
$0.013.94%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -74.65% | -44.62% | -31.32% | -16.32% | 62.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -74.65% | -44.62% | -31.32% | -16.32% | 62.84% |
| Cost of Revenue | -72.19% | -52.87% | -29.16% | -16.43% | 112.53% |
| Gross Profit | -78.40% | -33.50% | -33.75% | -16.19% | 20.00% |
| SG&A Expenses | 231.44% | 11.81% | 15.01% | 14.05% | -8.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.05% | -22.44% | -7.10% | 5.86% | 29.85% |
| Operating Income | -576.72% | -102.47% | -144.04% | -164.48% | 29.08% |
| Income Before Tax | -583.40% | -141.28% | -147.87% | -69.80% | 29.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -583.40% | -141.28% | -147.87% | -69.80% | 29.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 46.27% | 103.54% | 109.86% | 146.74% | 69.81% |
| Net Income | -1,106.52% | -170.29% | -181.71% | -39.09% | 55.25% |
| EBIT | -576.72% | -102.47% | -144.04% | -164.48% | 29.08% |
| EBITDA | -601.96% | -113.41% | -141.82% | -161.79% | 29.79% |
| EPS Basic | -1,066.67% | -160.00% | -171.43% | -36.00% | 57.14% |
| Normalized Basic EPS | -2,340.00% | -128.57% | -250.00% | -300.00% | 77.27% |
| EPS Diluted | -1,066.67% | -160.00% | -171.43% | -36.00% | 57.14% |
| Normalized Diluted EPS | -2,340.00% | -128.57% | -250.00% | -300.00% | 77.27% |
| Average Basic Shares Outstanding | 2.82% | 2.28% | 2.37% | 3.81% | 4.36% |
| Average Diluted Shares Outstanding | 2.82% | 2.28% | 2.37% | 3.81% | 4.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |